The INSULIN Act of 2026 mandates that group and individual health insurance plans cap out-of-pocket costs for selected insulin products at $35 per 30-day supply, effective for plan years beginning on or after January 1, 2028. This cost limit applies to a variety of insulin types and delivery devices, with the cap set at the lesser of $35 or 25 percent of the negotiated price net of concessions. The bill also prohibits insurers from imposing deductibles or prior authorization requirements for these covered products unless clinically justified for safety reasons.
Additionally, the legislation directs the Department of Health and Human Services to fund a resource center and hotline to help uninsured individuals find affordable insulin assistance programs, while requiring the Government Accountability Office to study the demographics of uninsured insulin users. Finally, it creates an expedited review process for biosimilar insulin applications when the Secretary determines there is inadequate competition in the market.
The SUSTAIN 340B Act overhauls the federal drug discount program to tighten oversight and prevent fraud by requiring covered entities to register their contract pharmacies and child sites with the Department of Health and Human Services. It establishes a new independent data clearinghouse to track claims and stop duplicate discounts, while also mandating that health insurers and pharmacy benefit managers treat 340B providers on equal footing without imposing discriminatory reimbursement terms. The bill defines strict criteria for what constitutes a valid patient relationship and authorizes a user fee program starting in fiscal year 2031 to fund additional audits and enforcement activities. These provisions directly affect safety-net healthcare providers, drug manufacturers, and insurance companies by increasing transparency requirements and expanding the government's authority to penalize non-compliance.
This bill amends Medicare to cover dental and oral health services for the first time, affecting all current and future Medicare beneficiaries. It defines covered services to include routine cleanings, fillings, extractions, root canals, crowns, dentures, and emergency care. For most individuals, federal payment for these services will gradually increase from 0% to 80% over an eight-year period, while low-income individuals eligible for prescription drug subsidies will receive 80% coverage immediately. The legislation also establishes frequency limits, such as two cleanings and exams per year and a five-year limit on full dentures, and requires the U.S. Preventive Services Task Force to include at least one oral health professional.
The Fair Prescription Pricing Act of 2026 would cap the out-of-pocket costs that individuals pay for prescription drugs by limiting deductibles, copayments, and coinsurance to no more than the nationwide average consumer price for that specific medication. This provision applies to both group health plans and individual health insurance policies, ensuring that patients using in-network pharmacies do not face charges higher than the standard market rate. The bill requires pharmacy benefit managers to adhere to these same cost-sharing limits as the insurance providers themselves. These restrictions would be implemented across federal laws governing public health services, employee retirement income security, and internal revenue codes to ensure consistent enforcement for plan years beginning after the act's enactment.
The Part D Premium Protection Act of 2026 would establish a temporary premium credit for Medicare Part D prescription drug plan enrollees in 2027. This credit is designed to match the average premium reduction observed during the Part D Premium Stabilization Demonstration program between January 1, 2025, and the end of 2026. Under the bill's provisions, insurance sponsors would charge enrollees their standard premiums minus this specific credit amount, with the floor set at zero dollars. The Secretary of Health and Human Services would then reimburse the sponsors for the difference between the charged premium and the full applicable rate.
This Senate resolution designates the first week of August 2026 as "National Community Health Center Week" to recognize the role these facilities play in providing affordable primary care across the United States. The bill highlights that community health centers serve a diverse range of populations, including those in rural and urban areas, by offering integrated services such as mental health, dental, and pharmacy care. It encourages the general public to participate in the observance by visiting local centers and celebrating the partnership between these organizations and their communities.
The Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 requires federal agencies to include reasonable pricing clauses in all research grants and contracts involving biomedical products. Under this provision, U.S. residents cannot be charged more than the median price found in Canada and six other high-income OECD countries for any drug, device, or therapy developed with federal support. The Secretary of Health and Human Services is authorized to establish additional regulations, such as mechanisms to lower prices when revenues exceed targets or costs per health benefit are too high, while retaining the ability to waive these obligations if doing so serves the public interest. To ensure accountability, manufacturers must report clinical trial costs, government subsidies, and annual revenues by county, with all data made publicly available.
The Veterans Medicare Premium Transparency Act requires Medicare to clearly explain how a veteran's enrollment in the Department of Veterans Affairs patient enrollment system affects their monthly insurance premiums. Under this bill, annual notices sent to Medicare beneficiaries will explicitly state that time spent in the VA system counts toward premium calculations and qualifies as valid prescription drug coverage. Additionally, the Secretary of Health and Human Services must post this explanation on the Medicare website and submit a report to Congress within 180 days detailing the updates and estimating how many veterans were previously paying higher premiums due to this lack of clarity.
This resolution expresses support for designating the first week of August as National Community Health Center Week to honor the contributions of these facilities. It encourages all Americans to visit their local health centers during this time to celebrate the partnership between these organizations and the communities they serve. The bill highlights how community health centers provide affordable, comprehensive care to millions of people, particularly in rural and underserved areas, while integrating services like dental care, behavioral health, and pharmacy support. By recognizing these centers, the resolution aims to raise awareness of their role in improving public health outcomes and supporting local economies.
This bill modifies the Public Health Service Act to simplify the process for reviewing biosimilar drugs, which are generic versions of existing biologic medicines. By removing a specific requirement and renumbering a related clause, the legislation aims to reduce regulatory hurdles for manufacturers seeking approval for these products. The change directly impacts pharmaceutical companies and the FDA, potentially allowing for a more efficient evaluation of biosimilars without altering the fundamental safety standards.
